TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
+$0.14 today
- Market cap
- $87.31M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
Volume 0.19M
Average 0.85M
HURA Total Liabilities
Everything the company owes to creditors and other parties.
TuHURA Biosciences, Inc.NASDAQ: HURA
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 36.2% from a year ago
Total liabilities stood at $6.51M at the end of Q1 FY2026, up 36.2% from a year earlier and up 1.5% from the prior quarter. Over 3 fiscal years it compounded at +30.4% a year.
Context
- Total liabilities amounted to 21.9% of total assets at the end of Q1 FY2026, down 10.7 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +36.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.42M USD
- Year-over-year change
- +19.5%
- 4-year CAGR
- -2.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.42M | +19.5% |
| FY2024 | 2024-12-31 | 5.37M | -9.3% |
| FY2023 | 2023-12-31 | 5.92M | +104.7% |
| FY2022 | 2022-12-31 | 2.89M | -59.5% |
| FY2021 | 2021-12-31 | 7.15M | — |
Total Liabilities vs competitors
How HURA compares with its peers on the latest reported figures
- HURA's Mar 2026 total liabilities of $6.51M is the 7th highest of the 9 companies compared; the peer median is $44.93M.
- Its year-over-year change of +36.2% is the 2nd highest of 9, against a peer median of -17.7%.
- Total liabilities amounts to 21.9% of total assets for HURA, versus a peer median of 56.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $414.44M | -20.7% | +2.5% | 222.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | $112.62M | +161.3% | +133.2% | 168.6% |
| Mar 2026 | $91.12M | -19.9% | -34.7% | 77.5% | |
| Mar 2026 | $46.15M | -5.7% | +88.6% | 34.5% | |
| Mar 2026 | $43.71M | +21.3% | -26.4% | 87.8% | |
| Mar 2026 | $30.65M | -15.5% | -3.5% | 11.3% | |
| Mar 2026 | $6.51M | +36.2% | +30.4% | 21.9% | |
| Mar 2026 | $6.23M | -44.5% | +11.5% | 17.2% | |
| Mar 2026 | $6.09M | -86.1% | -41.3% | 10.3% | |
| Peer median (excluding HURA) | $44.93M | -17.7% | -0.5% | 56.0% | |
Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.55M | 14.25M | 3.67M | 12.66M | 3.62M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 101.42K | 334.44K | 222.7K | 0 |
| Inventory | 0 | 0 | 0 | 214.7K | 0 |
| Other Current Assets | 135.13K | 390.35K | 159.33K | 316.35K | 1M |
| Total Current Assets | 5.68M | 14.74M | 4.16M | 19.61M | 4.62M |
| Property, Plant & Equipment (Net) | 617.14K | 418.55K | 202.99K | 322.53K | 685.17K |
| Goodwill | 0 | 0 | 0 | 0 | 10.74M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 103.9K | 33.77K | 0 | 33.77K | 11.31M |
| Total Non-current Assets | 721.04K | 452.32K | 202.99K | 356.3K | 22.73M |
| Total Assets | 6.4M | 15.2M | 4.36M | 19.97M | 27.35M |
| Account Payables | 413.79K | 1.92M | 1.87M | 3.15M | 3.77M |
| Short-term Debt | 644.07K | 0 | 0 | 0 | 197.35K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 456K | 675K | 137K | 1.16M | 1.53M |
| Total Current Liabilities | 7.15M | 2.87M | 3.6M | 5.33M | 5.92M |
| Long-term Debt | 0 | 0 | 2.32M | 0 | 303.63K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 197.92K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 20.74K | 2.32M | 42.7K | 501.55K |
| Total Liabilities | 7.15M | 2.89M | 5.92M | 5.37M | 6.42M |
| Common Stock | 4.53K | 4.53K | 6.8K | 42.32K | 59.34K |
| Retained Earnings | (49.48M) | (59.16M) | (88.47M) | (111.12M) | (141.18M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (747.82K) | 12.3M | (1.56M) | 14.59M | 20.93M |
| Total Debt | 644.07K | 138.22K | 2.34M | 202.54K | 700.02K |
| Net Debt | (4.9M) | (14.11M) | (1.32M) | (12.45M) | (2.92M) |
TuHURA Biosciences, Inc.
NASDAQ:HURA
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.